BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 35716632)

  • 1. Dosimetric predictors of pneumonitis in locally advanced non-small cell lung cancer patients treated with chemoradiation followed by durvalumab.
    Gao RW; Day CN; Yu NY; Bush A; Amundson AC; Prodduturvar P; Majeed U; Butts E; Oliver T; Schwecke AJ; Moffett JN; Routman DM; Breen WG; Potter AL; Rivera-Concepcion J; Hoppe BS; Schild SE; Sio TT; Lou Y; Ernani V; Ko S; Olivier KR; Merrell KW; Garces YI; Manochakian R; Harmsen WS; Leventakos K; Owen D
    Lung Cancer; 2022 Aug; 170():58-64. PubMed ID: 35716632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of the incidence of ≥ grade 2 radiation pneumonitis between intensity-modulated radiotherapy and three-dimensional conformal radiotherapy in patients with unresectable non-small cell lung cancer treated with durvalumab after concurrent chemoradiotherapy.
    Masuo M; Shinohara E; Kitano M; Maruta R; Chonabayashi S; Endo S; Matumoto S; Nishiyama N; Machitori Y; Kobayashi M
    Jpn J Clin Oncol; 2024 Mar; 54(3):312-318. PubMed ID: 38010609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON).
    Saito G; Oya Y; Taniguchi Y; Kawachi H; Daichi F; Matsumoto H; Iwasawa S; Suzuki H; Niitsu T; Miyauchi E; Yokoi T; Yokoyama T; Uenami T; Sakata Y; Arai D; Okada A; Nagata K; Teraoka S; Kokubo M
    Lung Cancer; 2021 Nov; 161():86-93. PubMed ID: 34543942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and Risk Factors of Symptomatic Radiation Pneumonitis in Non-Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy and Consolidation Durvalumab.
    Shintani T; Kishi N; Matsuo Y; Ogura M; Mitsuyoshi T; Araki N; Fujii K; Okumura S; Nakamatsu K; Kishi T; Atsuta T; Sakamoto T; Narabayashi M; Ishida Y; Sakamoto M; Fujishiro S; Katagiri T; Kim YH; Mizowaki T
    Clin Lung Cancer; 2021 Sep; 22(5):401-410. PubMed ID: 33678582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of Pneumonitis in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation Followed by Consolidative Durvalumab.
    Diamond BH; Belani N; Masel R; DeCarli K; DiPetrillo T; Hepel JT; Azzoli CG; Khurshid H; Abbas A; Koffer PP
    Adv Radiat Oncol; 2023; 8(2):101130. PubMed ID: 36845618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pneumonitis After Concurrent Chemoradiation and Immune Checkpoint Inhibition in Patients with Locally Advanced Non-small Cell Lung Cancer.
    Altan M; Soto F; Xu T; Wilson N; Franco-Vega MC; Simbaqueba Clavijo CA; Shannon VR; Faiz SA; Gandhi S; Lin SH; Lopez P; Zhong L; Akhmedzhanov F; Godoy MCB; Shroff GS; Wu J; Khawaja F; Kim ST; Naing A; Heymach JV; Daniel-Macdougall C; Liao Z; Sheshadri A
    Clin Oncol (R Coll Radiol); 2023 Oct; 35(10):630-639. PubMed ID: 37507279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical features and risk factors for interstitial lung disease spreading in low-dose irradiated areas after definitive radiotherapy with or without durvalumab consolidation therapy for patients with non-small cell lung cancer.
    Sakagami M; Inokuchi H; Mukumoto N; Itoyama H; Hamaura N; Yamagishi M; Mukumoto N; Matsuda S; Kabata D; Shibuya K
    Radiat Oncol; 2023 May; 18(1):87. PubMed ID: 37217919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer.
    Mayahara H; Uehara K; Harada A; Kitatani K; Yabuuchi T; Miyazaki S; Ishihara T; Kawaguchi H; Kubota H; Okada H; Ninomaru T; Shindo C; Hata A
    Radiat Oncol; 2022 Jan; 17(1):7. PubMed ID: 35033139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective multicenter cohort study of durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis.
    Sugimoto T; Fujimoto D; Sato Y; Tamiya M; Yokoi T; Taniguchi Y; Hino A; Hata A; Uchida J; Fukuda Y; Hara S; Kanazu M; Matsumoto H; Kokubo M; Yamamoto N
    Lung Cancer; 2022 Sep; 171():3-8. PubMed ID: 35863254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of durvalumab after concurrent chemoradiation in Black patients with locally advanced non-small cell lung cancer.
    McCall NS; Janopaul-Naylor JR; McGinnis HS; Kesarwala AH; Tian S; Stokes WA; Shelton JW; Steuer CE; Carlisle JW; Leal TA; Ramalingam SS; Bradley JD; Higgins KA
    Cancer; 2023 Dec; 129(23):3713-3723. PubMed ID: 37354070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer.
    Nishimura A; Ono A; Wakuda K; Kawabata T; Yabe M; Miyawaki T; Miyawaki E; Kodama H; Nishioka N; Mamesaya N; Kobayashi H; Omori S; Kenmotsu H; Naito T; Murakami H; Harada H; Takahashi T
    Invest New Drugs; 2022 Apr; 40(2):403-410. PubMed ID: 34633575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The timing of durvalumab administration affects the risk of pneumonitis in patients with locally advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Yang Z; Zhong W; Luo Y; Wu C
    BMC Cancer; 2023 Oct; 23(1):962. PubMed ID: 37817073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial.
    Naidoo J; Vansteenkiste JF; Faivre-Finn C; Özgüroğlu M; Murakami S; Hui R; Quantin X; Broadhurst H; Newton M; Thiyagarajah P; Antonia SJ
    Lung Cancer; 2022 Apr; 166():84-93. PubMed ID: 35245844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients with unresectable stage III non-small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study criteria.
    Sakaguchi T; Ito K; Furuhashi K; Nakamura Y; Suzuki Y; Nishii Y; Taguchi O; Hataji O
    Respir Investig; 2019 Sep; 57(5):466-471. PubMed ID: 31104989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adding ipsilateral V20 and V30 to conventional dosimetric constraints predicts radiation pneumonitis in stage IIIA-B NSCLC treated with combined-modality therapy.
    Ramella S; Trodella L; Mineo TC; Pompeo E; Stimato G; Gaudino D; Valentini V; Cellini F; Ciresa M; Fiore M; Piermattei A; Russo P; Cesario A; D'Angelillo RM
    Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):110-5. PubMed ID: 19619955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pneumonitis After Chemoradiotherapy and Adjuvant Durvalumab in Stage III Non-Small Cell Lung Cancer.
    Edwards DM; Sankar K; Alseri A; Jiang R; Schipper M; Miller S; Dess K; Strohbehn GW; Elliott DA; Moghanaki D; Ramnath N; Green MD; Bryant AK
    Int J Radiat Oncol Biol Phys; 2024 Mar; 118(4):963-970. PubMed ID: 37793573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensity-modulated radiation therapy with concurrent chemotherapy followed by durvalumab for stage III non-small cell lung cancer: A multi-center retrospective study.
    Tsukita Y; Yamamoto T; Mayahara H; Hata A; Takeda Y; Nakayama H; Tanaka S; Uchida J; Usui K; Toyoda T; Tamiya M; Morimoto M; Oya Y; Kodaira T; Miyauchi E; Jingu K; Sugiura H
    Radiother Oncol; 2021 Jul; 160():266-272. PubMed ID: 34023330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis.
    Palma DA; Senan S; Tsujino K; Barriger RB; Rengan R; Moreno M; Bradley JD; Kim TH; Ramella S; Marks LB; De Petris L; Stitt L; Rodrigues G
    Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):444-50. PubMed ID: 22682812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis following concurrent chemoradiotherapy: a multicenter prospective cohort study.
    Sugimoto T; Fujimoto D; Sato Y; Tamiya M; Yokoi T; Tamiya A; Iwasawa S; Hata A; Uchida J; Fukuda Y; Hara S; Kanazu M; Hirano K; Kokubo M; Yamamoto N
    Invest New Drugs; 2021 Jun; 39(3):853-859. PubMed ID: 33405089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non-small cell lung cancer: Management of adverse events.
    Miura Y; Mouri A; Kaira K; Yamaguchi O; Shiono A; Hashimoto K; Nishihara F; Shinomiya S; Akagami T; Murayama Y; Abe T; Noda SE; Kato S; Kobayashi K; Kagamu H
    Thorac Cancer; 2020 May; 11(5):1280-1287. PubMed ID: 32160383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.